---
title: "NeuroSense plans PrimeC new drug filing with Health Canada for ALS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293473713.md"
description: "NeuroSense Therapeutics plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS, following a Pre-NDS meeting. The submission includes Phase 2b PARADIGM data demonstrating a 14.9-month median survival benefit (HR 0.35, p=0.0037)."
datetime: "2026-07-22T12:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293473713.md)
  - [en](https://longbridge.com/en/news/293473713.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293473713.md)
---

# NeuroSense plans PrimeC new drug filing with Health Canada for ALS

-   NeuroSense plans to file a New Drug Submission with Health Canada for PrimeC to treat ALS following a Pre-NDS meeting. \* The submission package includes Phase 2b PARADIGM data showing a 14.9-month median survival benefit (HR 0.35, p=0.0037). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220830PR\_NEWS\_USPR\_\_\_\_\_LN09247) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [18:11 ETRejuva Fresh® Announces Health Canada Approval for the Cutting-Edge PicoPretty® Q-Switched ND:YAG Laser](https://longbridge.com/en/news/293979851.md)
- [BUZZ-Outlook Therapeutics rises after US FDA approves eye disease drug](https://longbridge.com/en/news/293790916.md)
- [Sandoz partners with Adalvo to commercialize semaglutide in Brazil after ANVISA approval](https://longbridge.com/en/news/294183033.md)
- [US FDA advisers weigh restrictions on seven peptides as industry presses for expansion](https://longbridge.com/en/news/293644206.md)
- [US FDA approves over-the-counter Tylenol combination pill for pain relief](https://longbridge.com/en/news/293777794.md)